Cantor Fitzgerald Issues Negative Outlook for CAPR Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Capricor Therapeutics downward to ($2.33), from a previous estimate of ($1.98).
• Capricor's recent quarterly earnings report showed a loss of ($0.57) EPS, missing analyst expectations by $0.09.
• While Cantor Fitzgerald maintains an "Overweight" rating with a price target of $30.00, other analysts have issued conflicting ratings ranging from "sell" to "buy."

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Stock analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Capricor Therapeutics in a report released on Tuesday, August 12th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($2.33) for the year, down from their previous estimate of ($1.98). Cantor Fitzgerald has a "Overweight" rating and a $30.00 price objective on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. Cantor Fitzgerald also issued estimates for Capricor Therapeutics' FY2026 earnings at $0.67 EPS.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

A number of other analysts have also recently issued reports on CAPR. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 target price on shares of Capricor Therapeutics in a research note on Friday, July 11th. HC Wainwright cut their target price on shares of Capricor Therapeutics from $77.00 to $24.00 and set a "buy" rating for the company in a research note on Friday, July 11th. Finally, Oppenheimer cut their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research note on Monday, June 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $22.56.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $0.11 during midday trading on Thursday, reaching $8.19. The stock had a trading volume of 49,440 shares, compared to its average volume of 2,023,928. The stock has a 50-day moving average of $9.40 and a 200-day moving average of $11.08. The company has a market capitalization of $374.40 million, a price-to-earnings ratio of -4.97 and a beta of 0.59. Capricor Therapeutics has a 12-month low of $3.84 and a 12-month high of $23.40.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its holdings in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in Capricor Therapeutics during the 4th quarter valued at about $68,000. Citizens Financial Group Inc. RI bought a new stake in Capricor Therapeutics during the 1st quarter valued at about $95,000. Finally, KLP Kapitalforvaltning AS lifted its holdings in Capricor Therapeutics by 65.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company's stock valued at $108,000 after buying an additional 4,300 shares in the last quarter. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.